News
May 15, 2026
AbstractSystemic amyloid light-chain (AL) amyloidosis is characterized by the extracellular deposition of misfolded immunoglobulin light chains in tissues and is…
May 14, 2026
Overview The purpose of this study is to:Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment,…
May 14, 2026
OverviewTransthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training…
May 14, 2026
Position: The Development Manager for the Amyloidosis Research Consortium (ARC) will be responsible for managing the full lifecycle of donor data, from initial…
May 14, 2026
Differences versus placebo seen within 30 days, sustained to 30 monthsNew analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart…
May 14, 2026
73% of Respondents Had Never Heard of ATTR-CM, a Serious Heart Condition Where Women Face Later Diagnosis, Lower Treatment Rates, And Worse Outcomes CHICAGO,…
May 14, 2026
Cardiac amyloidosis on nuclear imaging of the heart using 11C-PiB PET/CT. Image courtesy of RSNACardiac amyloidosis research is a growing area in cardiology thanks…
May 13, 2026
OverviewThe study is conducted in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a heart disease that occurs in people with the disease ATTR…
May 13, 2026
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as a significant yet frequently overlooked etiology of heart failure, particularly within the elderly…
May 13, 2026
At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…